VYNE Therapeutics Inc.

VYNE Therapeutics Inc.

Biotechnology • Healthcare • Bridgewater, NJ, United States • VYNE (NCM)

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

800 775 7936 685 Route 202/206 N, Bridgewater, NJ 08807, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement - Yahoo Finance
Yahoo Finance • Dec 17
Vyne Therapeutics stock soars after merger with Yarrow Bioscience - Investing.com
Investing.com • Dec 17
VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders - Business Wire
Business Wire • Dec 17
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE) - PR Newswire
PR Newswire • Dec 17
New biotech merger backs antibody targeting Graves’ and thyroid eye disease - Stock Titan
Stock Titan • Dec 17

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has VYNE Therapeutics Inc. had layoffs?
No layoff events have been recorded for VYNE Therapeutics Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does VYNE Therapeutics Inc. have?
VYNE Therapeutics Inc. has approximately 13 employees.
What industry is VYNE Therapeutics Inc. in?
VYNE Therapeutics Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is VYNE Therapeutics Inc. a publicly traded company?
Yes, VYNE Therapeutics Inc. is publicly traded under the ticker symbol VYNE on the NCM. The company has a market capitalization of approximately $0.02 billion.
Where is VYNE Therapeutics Inc. headquartered?
VYNE Therapeutics Inc. is headquartered in Bridgewater, NJ, United States at 685 Route 202/206 N, Bridgewater, NJ 08807, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.